{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:14:30Z","timestamp":1789146870457,"version":"build-2803163510"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lungcan.2026.109603","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:12:14Z","timestamp":1788045134000},"page":"109603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Large cell neuroendocrine carcinoma of the lung: Current standards, emerging targets, and translational foundations"],"prefix":"10.1016","volume":"220","author":[{"given":"Georgia","family":"Hardavella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Sochorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2843-3863","authenticated-orcid":false,"given":"Armin","family":"Frille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Karampinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5822-4363","authenticated-orcid":false,"given":"Maria","family":"Tolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra Kralova","family":"Viziova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1671-5540","authenticated-orcid":false,"given":"Katherina Bernadette","family":"Sreter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-7220","authenticated-orcid":false,"given":"Rebecca C.","family":"Rancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Xhemalaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6736-1287","authenticated-orcid":false,"given":"Ilona","family":"Tietzova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109603_b0005","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/jcm11051461","article-title":"Large cell neuroendocrine carcinoma of the lung: current understanding and challenges","volume":"11","author":"Andrini","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2026.109603_b0010","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.cllc.2019.07.011","article-title":"Large-cell neuroendocrine carcinoma of the lung: a population-based study","volume":"21","author":"Kinslow","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0015","doi-asserted-by":"crossref","first-page":"e6539","DOI":"10.7717\/peerj.6539","article-title":"Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study","volume":"7","author":"Cao","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.lungcan.2026.109603_b0020","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S1470-2045(24)00374-7","article-title":"Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies","volume":"26","author":"Sen","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1183\/13993003.00618-2015","article-title":"Clinical features of large cell neuroendocrine carcinoma: a population-based overview","volume":"47","author":"Derks","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2026.109603_b0030","doi-asserted-by":"crossref","first-page":"e20515","DOI":"10.1200\/JCO.2021.39.15_suppl.e20515","article-title":"Large cell neuroendocrine carcinoma of the lung: prognostic factors to predict clinical outcomes","volume":"39","author":"Andrini","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0035","first-page":"3636","article-title":"Lung large cell neuroendocrine carcinoma: an analysis of patients from the surveillance, epidemiology, and end-results (SEER) database","volume":"25","author":"Deng","year":"2019","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0040","first-page":"2143","article-title":"Outcomes for surgery in large cell lung neuroendocrine cancer","volume":"14","author":"Raman","year":"2019","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109603_b0045","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/cam4.2188","article-title":"The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung","volume":"8","author":"Gu","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2026.109603_b0050","doi-asserted-by":"crossref","unstructured":"K.M. Fong, A. Rosenthal, D.J. Giroux, K.K. Nishimura, J. Erasmus, Y. Lievens, et al., The international association for the study of lung cancer staging project for lung cancer: proposals for the revision of the M descriptors in the forthcoming ninth edition of the TNM classification for lung cancer. J. Thorac. Oncol., 2024;19:786\u2013802. Doi: 10.1016\/j.jtho.2024.01.019.","DOI":"10.1016\/j.jtho.2024.01.019"},{"key":"10.1016\/j.lungcan.2026.109603_b0055","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jtho.2024.02.011","article-title":"The international association for the study of lung cancer lung cancer staging project: proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer","volume":"19","author":"Rami-Porta","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0060","doi-asserted-by":"crossref","unstructured":"J. Huang, R.U. Osarogiagbon, D.J. Giroux, K.K. Nishimura, A. Bille, G. Cardillo, et al., The international association for the study of lung cancer staging project for lung cancer: proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer. J. Thorac. Oncol., 2024;19:766\u201385. Doi: 10.1016\/j.jtho.2023.10.012.","DOI":"10.1016\/j.jtho.2023.10.012"},{"key":"10.1016\/j.lungcan.2026.109603_b0065","doi-asserted-by":"crossref","unstructured":"M.S. Tsao, A. Rosenthal, A.G. Nicholson, F. Detterbeck, W.E.E. Eberhardt, Y. Lievens, et al., The international association for the study of lung cancer staging project: the database and proposal for the revision of the staging of pulmonary neuroendocrine carcinoma in the forthcoming ninth edition of the TNM classification for lung cancer. J. Thorac. Oncol., 2025;20:856\u201370. Doi: 10.1016\/j.jtho.2025.01.013.","DOI":"10.1016\/j.jtho.2025.01.013"},{"key":"10.1016\/j.lungcan.2026.109603_b0070","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3390\/cancers13081753","article-title":"Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States","volume":"13","author":"Shah","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109603_b0075","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/his.13800","article-title":"Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?","volume":"74","author":"Derks","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2026.109603_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.673901","article-title":"Comprehensive dissection of treatment patterns and outcome for patients with metastatic large-cell neuroendocrine lung carcinoma","volume":"11","author":"Fisch","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0085","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.cllc.2016.01.003","article-title":"Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes","volume":"17","author":"Naidoo","year":"2016","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0090","article-title":"Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung: the Japanese lung cancer registry study","volume":"204","author":"Shirai","year":"2025","journal-title":"Lung Cancer Amst Neth."},{"key":"10.1016\/j.lungcan.2026.109603_b0095","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2174\/0929867321666131129125953","article-title":"Neuroendocrine tumors of the lung: hystological classification, diagnosis, traditional and new therapeutic approaches","volume":"21","author":"Cueto","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.lungcan.2026.109603_b0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.35125","article-title":"Contemporary incidence and survival of lung neuroendocrine neoplasms","volume":"8","author":"Hallet","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lungcan.2026.109603_b0105","unstructured":"WHO Classification of Tumours Editorial Board. Thoracic tumours. 5th ed. Vol. 5. Lyon (France): International Agency for Research on Cancer; 20(WHO classification of tumours series)."},{"key":"10.1016\/j.lungcan.2026.109603_b0110","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00000478-199106000-00003","article-title":"Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases","volume":"15","author":"Travis","year":"1991","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0115","doi-asserted-by":"crossref","unstructured":"S. Mukhopadhyay, J.K. Dermawan, C.P. Lanigan, C.F. Farver, Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod. Pathol. Off. J. U S Can. Acad. Pathol. Inc., 2019;32:100\u20139. Doi: 10.1038\/s41379-018-0122-7.","DOI":"10.1038\/s41379-018-0122-7"},{"key":"10.1016\/j.lungcan.2026.109603_b0120","doi-asserted-by":"crossref","unstructured":"N. Rekhtman, Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod. Pathol. Off. J. U S Can. Acad. Pathol. Inc., 2022;35:36\u201350. Doi: 10.1038\/s41379-021-00943-2.","DOI":"10.1038\/s41379-021-00943-2"},{"key":"10.1016\/j.lungcan.2026.109603_b0125","doi-asserted-by":"crossref","first-page":"860","DOI":"10.21037\/tlcr.2020.02.13","article-title":"Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis","volume":"9","author":"Baine","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncy.21972","article-title":"Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens","volume":"126","author":"Doxtader","year":"2018","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0135","doi-asserted-by":"crossref","unstructured":"N. Rekhtman, C.M. Pietanza, J. Sabari, J. Montecalvo, H. Wang, O. Habeeb, et al., Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Mod. Pathol. Off. J. U S Can. Acad. Pathol. Inc., 2018;31:111\u201321. Doi: 10.1038\/modpathol.2017.110.","DOI":"10.1038\/modpathol.2017.110"},{"key":"10.1016\/j.lungcan.2026.109603_b0140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ijc.33853","article-title":"In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma","volume":"150","author":"Hermans","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1449490","article-title":"Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma","volume":"14","author":"Kang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00292-015-0030-2","article-title":"Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?","volume":"36","author":"Schnabel","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.lungcan.2026.109603_b0155","first-page":"362","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109603_b0160","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41416-021-01407-9","article-title":"Large cell neuroendocrine lung carcinoma: consensus statement from the British Thoracic Oncology Group and the Association of Pulmonary Pathologists","volume":"125","author":"Lindsay","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0165","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/1759-7714.12576","article-title":"Pathological diagnosis of pulmonary large cell neuroendocrine carcinoma by endobronchial ultrasound-guided transbronchial needle aspiration","volume":"9","author":"Inage","year":"2018","journal-title":"Thorac. Cancer."},{"key":"10.1016\/j.lungcan.2026.109603_b0170","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2559.2010.03486.x","article-title":"Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability","volume":"56","author":"den Bakker","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2026.109603_b0175","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4132\/KoreanJPathol.2012.46.1.42","article-title":"Interobserver variability in diagnosing high-grade neuroendocrine carcinoma of the lung and comparing it with the morphometric analysis","volume":"46","author":"Ha","year":"2012","journal-title":"Korean J. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0180","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0185","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1078-0432.CCR-16-0355","article-title":"Genomic profiling of large-cell neuroendocrine carcinoma of the lung","volume":"23","author":"Miyoshi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0190","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41467-018-03099-x","article-title":"Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors","volume":"9","author":"George","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109603_b0195","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/cam4.1172","article-title":"Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor","volume":"6","author":"Inamura","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2026.109603_b0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/ERC-17-0427","article-title":"Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors","volume":"25","author":"Kasajima","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0205","first-page":"636","article-title":"Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung","volume":"13","author":"Kim","year":"2018","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109603_b0210","article-title":"IASLC update on classification of pulmonary neuroendocrine neoplasms","volume":"103977","author":"Beasley","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0215","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1038\/s41467-019-11276-9","article-title":"Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids","volume":"10","author":"Alcala","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109603_b0220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","article-title":"Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome","volume":"24","author":"Derks","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001999","article-title":"Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung","volume":"9","author":"Dudnik","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0230","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1038\/s41467-025-63091-0","article-title":"Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma","volume":"16","author":"Nassar","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109603_b0235","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2022.01.007","article-title":"The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese lung large cell neuroendocrine carcinoma","volume":"166","author":"Li","year":"2022","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107454","article-title":"Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma","volume":"188","author":"Burns","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0245","article-title":"Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor","volume":"192","author":"Li","year":"2024","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0250","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","article-title":"Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system","volume":"12","author":"Yachida","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109603_b0255","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937972","article-title":"PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 \u2018EPNEC\u2019 study","volume":"12","author":"Arpin","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0260","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2018.02.003","article-title":"PD-L1 expression in large cell neuroendocrine carcinoma of the lung","volume":"118","author":"Eichhorn","year":"2018","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0265","doi-asserted-by":"crossref","unstructured":"B.C.M. Hermans, J.L. Derks, E. Thunnissen, R.J. van Suylen, M.A. den Bakker, H.J.M. Groen, et al., Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer. Amsterdam, Netherlands; 2019;130:179\u201386. Doi: 10.1016\/j.lungcan.2019.02.022.","DOI":"10.1016\/j.lungcan.2019.02.022"},{"key":"10.1016\/j.lungcan.2026.109603_b0270","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2017.03.006","article-title":"PD-L1 expression in neuroendocrine tumors of the lung","volume":"108","author":"Tsuruoka","year":"2017","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0275","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13000-018-0712-1","article-title":"Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors","volume":"13","author":"Wang","year":"2018","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0280","first-page":"3243","article-title":"Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung","volume":"10","author":"Ohtaki","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0285","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lungcan.2020.03.008","article-title":"Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)","volume":"143","author":"Sherman","year":"2020","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0290","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2019.10.010","article-title":"DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile","volume":"138","author":"Hermans","year":"2019","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0295","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0300","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12022-025-09854-3","article-title":"DLL3 expression in neuroendocrine carcinomas and neuroendocrine tumours: insights from a multicentric cohort of 1294 pulmonary and extrapulmonary neuroendocrine neoplasms","volume":"36","author":"Schmitt","year":"2025","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0305","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cllc.2026.01.003","article-title":"Management of pulmonary large-cell neuroendocrine carcinoma (LCNEC): an updated review","volume":"27","author":"Yeung","year":"2026","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0310","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s11864-022-01026-3","article-title":"Surgical principles in the management of lung neuroendocrine tumors: open questions and controversial technical issues","volume":"23","author":"Brascia","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0315","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.athoracsur.2014.10.015","article-title":"Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung","volume":"99","author":"Eichhorn","year":"2015","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109603_b0320","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ejcts\/ezs174","article-title":"Surgical management of pulmonary large cell neuroendocrine carcinomas: a 10-year experience","volume":"43","author":"Fournel","year":"2013","journal-title":"Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109603_b0325","first-page":"339","article-title":"Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma: results from the European Society for Thoracic Surgeons Lung Neuroendocrine Tumours Retrospective Database","volume":"52","author":"Filosso","year":"2017","journal-title":"Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109603_b0330","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3390\/cancers15061695","article-title":"The surgical management of lung neuroendocrine neoplasms","volume":"15","author":"Soldath","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109603_b0335","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atssr.2024.12.003","article-title":"Outcomes with sublobar resection vs lobectomy in patients with cT1N0M0 large-cell neuroendocrine cancer","volume":"3","author":"Suzuki","year":"2025","journal-title":"Ann. Thorac. Surg. Short Rep."},{"key":"10.1016\/j.lungcan.2026.109603_b0340","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1007\/s10238-023-01071-8","article-title":"Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches","volume":"23","author":"Khan","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.lungcan.2026.109603_b0345","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.3390\/cancers13235948","article-title":"Effect of adjuvant and palliative chemotherapy in large cell neuroendocrine carcinoma of the lung: a systematic review and meta-analysis","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109603_b0350","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.lungcan.2019.11.004","article-title":"Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: a multi-center retrospective study","volume":"139","author":"Zhang","year":"2020","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0355","doi-asserted-by":"crossref","first-page":"71","DOI":"10.21037\/tlcr-20-374","article-title":"Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States","volume":"10","author":"May","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0360","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9761826","article-title":"Small or non-small cell lung cancer based therapy for treatment of large cell neuroendocrine cancer of the lung? University of cincinnati experience","volume":"2018","author":"Eldessouki","year":"2018","journal-title":"J. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0365","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40001-015-0158-9","article-title":"Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas","volume":"20","author":"Rieber","year":"2015","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0370","doi-asserted-by":"crossref","first-page":"LMT32","DOI":"10.2217\/lmt-2020-0004","article-title":"Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung","volume":"9","author":"Wegner","year":"2020","journal-title":"Lung Cancer Manag."},{"key":"10.1016\/j.lungcan.2026.109603_b0375","article-title":"Stereotactic or conventional radiation for early-stage non-small cell lung cancer: a systematic review and meta-analysis","volume":"15","author":"Mutsaers","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.lungcan.2026.109603_b0380","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ijrobp.2020.10.004","article-title":"Stereotactic body radiation therapy for mediastinal and hilar lymph node metastases","volume":"109","author":"Shahi","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109603_b0385","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0390","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1236361","article-title":"IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center","volume":"13","author":"Le Roy","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0395","doi-asserted-by":"crossref","first-page":"S2474","DOI":"10.21037\/jtd.2018.07.29","article-title":"Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy","volume":"10","author":"Yegya-Raman","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2026.109603_b0400","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jtcvs.2008.12.037","article-title":"Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma","volume":"138","author":"Iyoda","year":"2009","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2026.109603_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.653162","article-title":"Management of large cell neuroendocrine carcinoma","volume":"11","author":"Corbett","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0410","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/cancers18060964","article-title":"Interventional clinical trials in metastatic pulmonary large-cell neuroendocrine carcinoma: a systematic review of prospective, interventional trials","volume":"18","author":"Merola","year":"2026","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109603_b0415","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/0284186X.2023.2212411","article-title":"Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms","volume":"62","author":"Dam","year":"2023","journal-title":"Acta Oncol. Stockholm, Sweden"},{"key":"10.1016\/j.lungcan.2026.109603_b0420","doi-asserted-by":"crossref","first-page":"8774","DOI":"10.1200\/JCO.2005.02.8233","article-title":"Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung","volume":"23","author":"Rossi","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0425","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/annonc\/mdt009","article-title":"Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study","volume":"24","author":"Le Treut","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0430","article-title":"Treatment outcomes in patients with stage IV large cell neuroendocrine carcinoma: a nationwide registry study","volume":"210","author":"Heijboer","year":"2025","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0435","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/jcm15020619","article-title":"Optimal treatment strategies for pulmonary large cell neuroendocrine carcinoma based on molecular subtypes","volume":"15","author":"Y\u00fccel","year":"2026","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2026.109603_b0440","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3892\/ol.2024.14268","article-title":"Efficacy of immune checkpoint inhibitors in advanced large cell neuroendocrine carcinoma of the lung: a single\u2011institution experience","volume":"27","author":"Yan","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.lungcan.2026.109603_b0445","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12885-023-10952-w","article-title":"Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study","volume":"23","author":"Song","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0450","article-title":"Performance of an RNA-based next-generation sequencing assay for combined detection of clinically actionable fusions and hotspot mutations in NSCLC","volume":"3","author":"Desmeules","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109603_b0455","article-title":"Molecular characterization and prognostication of large cell neuroendocrine carcinoma and large cell carcinoma","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0460","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.lungcan.2022.02.013","article-title":"Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer","volume":"166","author":"Claerhout","year":"2022","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0465","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/pharmaceutics17040520","article-title":"Targeting DLL3: innovative strategies for tumor treatment","volume":"17","author":"Wang","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lungcan.2026.109603_b0470","article-title":"Brief report: multi-institution real-world analysis evaluating safety, efficacy, and ctDNA dynamics after tarlatamab in patients with previously treated SCLC and LCNEC","volume":"7","author":"Fenton","year":"2026","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109603_b0475","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ijc.30472","article-title":"Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors","volume":"140","author":"Wang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0480","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1158\/0008-5472.CAN-22-0948","article-title":"A genomically and clinically annotated patient-derived xenograft resource for preclinical research in non-small cell lung cancer","volume":"82","author":"Woo","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216816","article-title":"Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies","volume":"588","author":"Yokota","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lungcan.2026.109603_b0490","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.ccell.2023.11.007","article-title":"Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites","volume":"41","author":"Dayton","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2026.109603_b0495","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","article-title":"Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening","volume":"10","author":"Kim","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109603_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1326426","article-title":"Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma","volume":"11","author":"Zhu","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.lungcan.2026.109603_b0505","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14737140.2025.2523544","article-title":"Modeling large cell neuroendocrine carcinoma of the lung for molecular, therapeutic and microenvironmental inferences: current knowledge and future perspectives","volume":"25","author":"Pelosi","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.lungcan.2026.109603_b0510","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/ejcts\/ezaa018","article-title":"Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy","volume":"57","author":"Filosso","year":"2020","journal-title":"Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109603_b0515","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000497037","article-title":"NETest liquid biopsy is diagnostic of lung neuroendocrine tumors and identifies progressive disease","volume":"108","author":"Malczewska","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.lungcan.2026.109603_b0520","article-title":"Pulmonary large cell neuroendocrine carcinoma","volume":"28","author":"Yang","year":"2022","journal-title":"Pathol Oncol Res POR."},{"key":"10.1016\/j.lungcan.2026.109603_b0525","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1097\/PAS.0000000000000916","article-title":"INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity","volume":"41","author":"Rooper","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0530","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.humpath.2015.09.019","article-title":"hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors","volume":"48","author":"Ye","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0535","article-title":"Pulmonary large cell neuroendocrine carcinoma: a rare type of non-small cell lung cancer","volume":"13","author":"Ng","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.lungcan.2026.109603_b0540","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1053\/hupa.2000.9076","article-title":"Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas","volume":"31","author":"Lyda","year":"2000","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0545","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/his.14679","article-title":"Comparative study of Rb1, cyclin D1 and p16 immunohistochemistry expression to distinguish lung small-cell carcinoma and large-cell neuroendocrine carcinoma","volume":"81","author":"Papaxoinis","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2026.109603_b0550","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1053\/j.semdp.2015.10.009","article-title":"What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?","volume":"32","author":"Pelosi","year":"2015","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0555","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/dc.24088","article-title":"Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas","volume":"46","author":"Yoxtheimer","year":"2018","journal-title":"Diagn. Cytopathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0560","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00428-004-1106-1","article-title":"CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas","volume":"445","author":"Pelosi","year":"2004","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0565","doi-asserted-by":"crossref","unstructured":"I.H. Ozbudak, K. Shilo, F. Tavora, N. Rassaei, W.-S. Chu, J. Fukuoka, et al., Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Mod. Pathol. Off. J. U S Can. Acad. Pathol. Inc., 2009;22:633\u20138. Doi: 10.1038\/modpathol.2009.6.","DOI":"10.1038\/modpathol.2009.6"},{"key":"10.1016\/j.lungcan.2026.109603_b0570","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/10668969211065757","article-title":"Expression of SATB2 in neuroendocrine carcinomas of the lung: frequent immunopositivity of large cell neuroendocrine carcinoma with a diagnostic pitfall","volume":"30","author":"Inoue","year":"2022","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0575","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1309\/AJCPGA0IUA8BHQEZ","article-title":"Evaluation of napsin a, TTF-1, p63, p40, and CK5\/6 immunohistochemical stains in pulmonary neuroendocrine tumors","volume":"142","author":"Zhang","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.lungcan.2026.109603_b0580","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/cas.13013","article-title":"Loss of YAP1 defines neuroendocrine differentiation of lung tumors","volume":"107","author":"Ito","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2026.109603_b0585","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Guidelines Version 1.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1448. Accessed 26 Apr 2026."},{"key":"10.1016\/j.lungcan.2026.109603_b0590","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462. Accessed 26 Apr 2026."},{"key":"10.1016\/j.lungcan.2026.109603_b0595","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Guidelines Version 5.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450. Accessed 26 Apr 2026."},{"key":"10.1016\/j.lungcan.2026.109603_b0600","doi-asserted-by":"crossref","first-page":"e251S","DOI":"10.1378\/chest.12-2356","article-title":"Diagnostic surgical pathology in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Schwartz","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2026.109603_b0605","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/annonc\/mdx268","article-title":"Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial","volume":"28","author":"Christopoulos","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0610","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.20.01806","article-title":"Randomized phase III Study of irinotecan plus cisplatin versus etoposide plus cisplatin for completely resected high-grade neuroendocrine carcinoma of the lung: JCOG1205\/1206","volume":"38","author":"Kenmotsu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0615","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/JTO.0b013e31828f6989","article-title":"Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study","volume":"8","author":"Niho","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0620","doi-asserted-by":"crossref","unstructured":"I.S. Sarkaria, A. Iyoda, M.S. Roh, G. Sica, D. Kuk, C.S. Sima, et al., Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Ann. Thorac. Surg., 2011;92:1180\u20136; discussion 1186-1187. Doi: 10.1016\/j.athoracsur.2011.05.027.","DOI":"10.1016\/j.athoracsur.2011.05.027"},{"key":"10.1016\/j.lungcan.2026.109603_b0625","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.lungcan.2012.04.009","article-title":"Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?","volume":"77","author":"Sun","year":"2012","journal-title":"Lung Cancer, Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0630","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01838-2016","article-title":"Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?","volume":"49","author":"Derks","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2026.109603_b0635","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2005.01.008","article-title":"Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy","volume":"49","author":"Yamazaki","year":"2005","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0640","article-title":"Brief report on the efficacy of nivolumab in patients with previously treated advanced large-cell neuroendocrine cancer of the lung","volume":"2","author":"Agar","year":"2021","journal-title":"JTO Clin Res Rep."},{"key":"10.1016\/j.lungcan.2026.109603_b0645","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1080\/0284186X.2023.2258444","article-title":"Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide","volume":"62","author":"\u00d8rting","year":"2023","journal-title":"Acta Oncol. Stockholm, Sweden"},{"key":"10.1016\/j.lungcan.2026.109603_b0650","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/jjco\/hyr065","article-title":"Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung","volume":"41","author":"Yoshida","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0655","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3892\/mco.2017.1198","article-title":"Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma","volume":"6","author":"Kasahara","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0660","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1038\/s41598-024-58327-w","article-title":"Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma","volume":"14","author":"Iida","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2026.109603_b0665","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10585-023-10250-6","article-title":"Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center","volume":"41","author":"Popov","year":"2024","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.lungcan.2026.109603_b0670","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/jrr\/rraa036","article-title":"The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis","volume":"61","author":"Cao","year":"2020","journal-title":"J. Radiat. Res. (Tokyo)."},{"key":"10.1016\/j.lungcan.2026.109603_b0675","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2020.10.001","article-title":"Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: a National Cancer Database analysis","volume":"150","author":"Limonnik","year":"2020","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0680","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2016.03.006","article-title":"Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice","volume":"95","author":"Metro","year":"2016","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0685","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/jjco\/hym053","article-title":"Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung","volume":"37","author":"Fujiwara","year":"2007","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109603_b0690","doi-asserted-by":"crossref","first-page":"00128","DOI":"10.1183\/23120541.00128-2016","article-title":"Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC","volume":"3","author":"Prelaj","year":"2017","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0695","article-title":"Outcome of pulmonary large cell neuroendocrine carcinoma after definitive treatment: a single-center retrospective review","volume":"17","author":"Sutanto","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.lungcan.2026.109603_b0700","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2006.03.007","article-title":"Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases","volume":"53","author":"Veronesi","year":"2006","journal-title":"Lung Cancer. Amsterdam, Netherlands"},{"key":"10.1016\/j.lungcan.2026.109603_b0705","first-page":"707","article-title":"The Role of systemic therapy in the management of stage I large cell neuroendocrine carcinoma of the lung","volume":"13","author":"Kujtan","year":"2018","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109603_b0710","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.7150\/jca.32446","article-title":"Double-edged role of radiotherapy in patients with pulmonary large-cell neuroendocrine carcinoma","volume":"10","author":"Jiang","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109603_b0715","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.21037\/jtd.2019.04.56","article-title":"Efficacy of perioperative chemotherapy for pulmonary high-grade neuroendocrine carcinomas: a propensity score matching analysis","volume":"11","author":"Ogawa","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2026.109603_b0720","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jtcvs.2019.09.077","article-title":"Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma","volume":"159","author":"Wakeam","year":"2020","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2026.109603_b0725","article-title":"Survival after lobectomy vs. sublobar resection for stage IA large-cell neuroendocrine carcinoma of the lung: a population-based study","volume":"9","author":"Yu","year":"2022","journal-title":"Front. Surg."},{"key":"10.1016\/j.lungcan.2026.109603_b0730","article-title":"Outcomes of patients with large cell neuroendocrine carcinoma of the lung after complete resect","author":"Han","year":"2017","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109603_b0735","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.athoracsur.2019.03.053","article-title":"Adjuvant therapy for patients with early large cell lung neuroendocrine cancer: a national analysis","volume":"108","author":"Raman","year":"2019","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109603_b0740","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12672-025-01777-z","article-title":"Survival outcomes of surgery and adjuvant chemotherapy in early-stage small cell and large cell lung cancer: a novel focus on tumors less than 1 cm","volume":"16","author":"Vazquez-Urrutia","year":"2025","journal-title":"Discov. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:54:42Z","timestamp":1789145682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":148,"alternative-id":["S0169500226006641"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109603","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Large cell neuroendocrine carcinoma of the lung: Current standards, emerging targets, and translational foundations","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109603"}}